Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Investors Business Daily

How Novo Nordisk Is Trying To Lengthen Its Lead In Weight Loss Over Eli Lilly

How Novo Nordisk Is Trying To Lengthen Its Lead In Weight Loss Over Eli Lilly

Novo Nordisk is planning to boost production for weight-loss shot Wegovy as Eli Lilly angles for approval. NVO stock surged Wednesday.

Investors Business Daily

Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments

Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity Treatments

Amgen stock surged Tuesday on a reportedly bullish call for its experimental obesity treatment — a potential rival to Novo and Lilly.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying.

Investors Business Daily

Novo Nordisk's Obesity Sales Nearly Doubled, But That Wasn't Enough For NVO Stock

Danish drugmaker Novo Nordisk missed quarterly views Wednesday, but raised its full-year outlook. Still, NVO stock tumbled.

Investors Business Daily

3 Stocks No One Is Talking About but Should Be

Amid an uncertain market, it becomes increasingly difficult for investors to find stocks that can survive the challenges and deliver solid returns. Accel Entertainment (ACEL), Novo Nordisk (NVO), and Titan Machinery (TITN) are currently not on investors’ radar, but it could be worth adding these stocks to one’s portfolio given…

inkl

Read news from The Economist, FT, and more,
with one subscription

Coal Stocks Today: Why Alliance Resource Partners Remains A Stock Market Leader

Coal Stocks Today: Why Alliance Resource Partners Remains A Stock Market Leader

Fund ownership has been increasing at Alliance Resource in at least the past three quarters.

Investors Business Daily

A new ‘miracle’ weight-loss drug really works — raising huge questions

A new ‘miracle’ weight-loss drug really works — raising huge questions

Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

Financial Times

IBD Screen Of The Day: Mutual Funds Are Buying These Energy Stocks

IBD Screen Of The Day: Mutual Funds Are Buying These Energy Stocks

Why solar, oil, and drug stocks may be ones to add to your watchlist.

Investors Business Daily

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

The Dow Jones rose despite a recession warning from Fed Chair Jerome Powell. Bitcoin tumbled again. Apple stock rose after a bullish call.

Investors Business Daily

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Tribune News Service

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

The Guardian - AU

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

Investors Business Daily

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Peering Into Novo Nordisk's Recent Short Interest

Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

Investors Business Daily

Here We Go Again: Stock Market Indexes Fade; Meta Platforms Soars, But GDP Falls In Q1

While earnings were mainly higher, the U.S. economy shrank in the first quarter.

Investors Business Daily

IBD Screen Of The Day: This One Snags Four Growth Stocks Near Buy Points

In today's IBD Screen Of The Day, the Stocks That Funds Are Buying filter reveals four compelling growth stocks near buy points of new bases. Three are in the energy field and one is a drugmaker. Novo Nordisk (NVO) has waffled a bit after breaking out above the 117.45 buy…

1 … 20 21 22 23

People

Dipanjan BanchurSince

Alex Oshmyansky

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prescription Drug

Places

266,735 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play